...
首页> 外文期刊>World journal of gastroenterology : >Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype
【24h】

Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype

机译:miR-196b和HOXA10的过表达是预后不良的胃癌亚型的特征

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AIM: To identify molecular biologic differences between two gastric adenocarcinoma subgroups presenting different prognoses through the analysis of microRNA and protein expression. METHODS: Array technologies were used to generate 1146 microRNAs and 124 proteins expression profiles of samples from 60 patients with gastric cancer. For the integrative analysis, we used established mRNA expression data published in our previous study. Whole mRNA expression levels were acquired from microarray data for 60 identical gastric cancer patients. Two gastric adenocarcinoma subgroups with distinct mRNA expression profiles presented distinctly different prognoses. MicroRNA and protein expression patterns were compared between gastric cancer tissue and normal gastric tissue and between two different prognostic groups. Aberrantly expressed microRNA, associated mRNA, and protein in patients with poor-prognosis gastric cancer were validated by quantitative reverse transcription polymerase chain reaction and immunochemistry in independent patients. RESULTS: We obtained the expression data of 1146 microRNAs and 124 cancer-related proteins. Four microRNAs were aberrantly expressed in the two prognostic groups and in cancer vs non-cancer tissues (P < 0.05). In the poor-prognosis group, miR-196b, miR- 135b, and miR-93 were up-regulated and miR-29c* was down-regulated. miR-196b expression positively correlated with Homeobox A10 (HOXA10) expression (r = 0.726, P < 0.001), which was significantly increased in poor-prognosis patients (P < 0.001). Comparing gastric cancer with non-cancer tissues, 46/124 proteins showed differential expression (P < 0.05); COX2 (P < 0.001) and cyclin B1 (P = 0.017) were clearly overexpressed in the poor-prognosis group. CONCLUSION: Co-activation of miR-196b and HOXA10 characterized a poor-prognosis subgroup of patients with gastric cancer. Elucidation of the biologic function of miR-196b and HOXA10 is warranted.
机译:目的:通过分析微小RNA和蛋白质表达,鉴定两个预后不同的胃腺癌亚组之间的分子生物学差异。方法:采用阵列技术从60例胃癌患者样本中产生1146个microRNA和124个蛋白质表达谱。对于整合分析,我们使用了先前研究中发表的既定的mRNA表达数据。从60名相同胃癌患者的微阵列数据中获得了完整的mRNA表达水平。两个具有不同mRNA表达谱的胃腺癌亚组的预后明显不同。比较了胃癌组织和正常胃组织以及两个不同预后组之间的MicroRNA和蛋白质表达模式。通过定量逆转录聚合酶链反应和免疫化学方法对独立患者的胃癌预后不良的患者中异常表达的microRNA,相关的mRNA和蛋白质进行了验证。结果:我们获得了1146个微RNA和124个癌症相关蛋白的表达数据。在两个预后组以及癌组织和非癌组织中异常表达了四个microRNA(P <0.05)。在预后不良组中,miR-196b,miR-135b和miR-93上调,而miR-29c *下调。 miR-196b表达与Homeobox A10(HOXA10)表达呈正相关(r = 0.726,P <0.001),在预后较差的患者中显着增加(P <0.001)。胃癌与非癌组织相比,46/124蛋白表达差异(P <0.05);在预后不良组中,COX2(P <0.001)和细胞周期蛋白B1(P = 0.017)明显过表达。结论:miR-196b和HOXA10的共同激活是胃癌患者预后不良的特征。有必要阐明miR-196b和HOXA10的生物学功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号